The IL11 Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the UM-UC-3 bladder carcinoma cell line by targeted disruption of the IL11 gene. This product provides a genetically heterogeneous pool of cells lacking interleukin-11 (IL-11) expression, enabling robust loss-of-function studies without clonal bias. Designed for advanced biomedical research, these cells facilitate investigation of IL-11-dependent signaling and phenotypes in cancer biology.
UM-UC-3 is an epithelial cell line established from a male patient with transitional cell carcinoma of the bladder. It displays adherent morphology and aggressive traits typical of high-grade disease, including rapid proliferation, tumorigenicity in vivo, and constitutive oncogenic signaling. As a widely employed bladder cancer model, UM-UC-3 supports research on cytokine-driven progression, tumor microenvironment interactions, and autocrine loops.
IL-11 is a pleiotropic cytokine of the IL-6 family that signals via a receptor complex of IL11RA and IL6ST (gp130). Ligand binding activates JAK1/JAK2, leading to STAT3 phosphorylation and nuclear translocation. Concurrently, GRB2/SOS1 triggers HRAS-RAF1-MAP2K1-MAPK1/3 (ERK), and PIK3CA activates AKT1. Upstream regulators TGFB1, IL1B, TNF, STAT3, NFKB1, JUN, and FOS can induce IL11 expression. Downstream targets include CCND1, MYC, BCL2L1, MMP9, and VEGFA, which promote cell cycle progression, survival, matrix remodeling, and angiogenesis. Negative regulators SOCS3 and PTPN11 (SHP2) dampen signaling.
In bladder carcinoma, IL-11 has been implicated in driving a pro-tumorigenic environment by stimulating proliferation, survival, invasion, and metastasis. UM-UC-3 cells endogenously express IL-11 and its receptors, creating an autocrine loop that sustains STAT3 activation and contributes to aggressive behavior. Thus, IL11 knockout in this model enables dissection of JAK/STAT3 and MAPK/ERK pathway contributions to bladder cancer, evaluation of gp130-dependent signaling, and therapeutic assessment of IL-11 axis inhibitors in a clinically relevant background.
This polyclonal knockout product supports a range of applications, including validation of IL-11 as a drug target, testing of JAK inhibitors, and mechanistic studies of metastasis and therapy resistance. Representative assays include western blotting for phospho-STAT3, RT-qPCR for downstream targets CCND1 and MYC, MTT/CCK-8 proliferation assays, Transwell migration and invasion assays, soft agar colony formation, xenograft tumor growth studies, RNA-seq transcriptomics, and cytokine array profiling. For further information, contact Ascent Research.
